INTRODUCTION: Although depression is a well-established feature of schizophrenia, it is difficult to measure, because it overlaps with negative symptoms and extrapyramidal symptoms (EPS). Routinely adopted depression scales were not designed to be used in--cases of schizophrenia, and are known to perform poorly when trying to distinguish depression from other symptoms. OBJECTIVE: The aim of this study was to evaluate the validity of the Brazilian version of the Calgary Depression Rating Scale for Schizophrenia (CDSS). METHOD: Outpatients from four mental health units in the city of São Paulo, diagnosed as having schizophrenia by DSM-IV criteria, were evaluated by two independent raters who applied the DSM-IV depression criteria. All patients were assessed by means of the CDSS, the Positive and Negative Syndrome Scale (PANSS), and the Extrapyramidal Symptom Rating Scale (ESRS). RESULTS: Eighty patients were recruited for the study. The analysis was carried out by comparing the DSM-IV criteria of depression with the CDSS scores, by means of the receiver operating characteristic (ROC) curves. The area under the ROC curve for major depression was 0.95 (SD = 0.02), and at a cut-off point of 6/7 the validity coefficients were as follows: sensibility 77%, specificity 92%, positive predictive value 67% and negative predictive value 95%. The area under the ROC curve for minor depression was 0.95 (SD = 0.02), and at a cut-off point of 4/5 the validity coefficients were as follows: sensibility 95%, specificity 88%, positive predictive value 75% and negative predictive value 98%. The correlation coefficients between the CDSS scores, the PANSS negative and positive subscale scores, and the ESRS scores were all below 0.50. CONCLUSION: It can be concluded that the Brazilian version of the CDSS is a valid research tool to assess depressive episodes for stabilized patients with schizophrenia.
INTRODUCTION: Although depression is a well-established feature of schizophrenia, it is difficult to measure, because it overlaps with negative symptoms and extrapyramidal symptoms (EPS). Routinely adopted depression scales were not designed to be used in--cases of schizophrenia, and are known to perform poorly when trying to distinguish depression from other symptoms. OBJECTIVE: The aim of this study was to evaluate the validity of the Brazilian version of the Calgary Depression Rating Scale for Schizophrenia (CDSS). METHOD: Outpatients from four mental health units in the city of São Paulo, diagnosed as having schizophrenia by DSM-IV criteria, were evaluated by two independent raters who applied the DSM-IV depression criteria. All patients were assessed by means of the CDSS, the Positive and Negative Syndrome Scale (PANSS), and the Extrapyramidal Symptom Rating Scale (ESRS). RESULTS: Eighty patients were recruited for the study. The analysis was carried out by comparing the DSM-IV criteria of depression with the CDSS scores, by means of the receiver operating characteristic (ROC) curves. The area under the ROC curve for major depression was 0.95 (SD = 0.02), and at a cut-off point of 6/7 the validity coefficients were as follows: sensibility 77%, specificity 92%, positive predictive value 67% and negative predictive value 95%. The area under the ROC curve for minor depression was 0.95 (SD = 0.02), and at a cut-off point of 4/5 the validity coefficients were as follows: sensibility 95%, specificity 88%, positive predictive value 75% and negative predictive value 98%. The correlation coefficients between the CDSS scores, the PANSS negative and positive subscale scores, and the ESRS scores were all below 0.50. CONCLUSION: It can be concluded that the Brazilian version of the CDSS is a valid research tool to assess depressive episodes for stabilized patients with schizophrenia.
Authors: Cecília Attux; Larissa C Martini; Hélio Elkis; Sérgio Tamai; Andréa Freirias; Maria das Graças Miquelutti Camargo; Mário Dinis Mateus; Jair de Jesus Mari; André F Reis; Rodrigo A Bressan Journal: BMC Psychiatry Date: 2013-02-18 Impact factor: 3.630
Authors: Peter Ventevogel; Gieljan De Vries; Willem F Scholte; Nasratullah Rasa Shinwari; Hafizullah Faiz; Ruhullah Nassery; Wim van den Brink; Miranda Olff Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2007-02-13 Impact factor: 4.519
Authors: Cristiano Noto; Vanessa Kiyomi Ota; Eduardo S Gouvea; Lucas B Rizzo; Leticia M N Spindola; Pedro H S Honda; Quirino Cordeiro; Sintia Iole Belangero; Rodrigo Affonseca Bressan; Ary Gadelha; Michael Maes; Elisa Brietzke Journal: Int J Neuropsychopharmacol Date: 2014-10-31 Impact factor: 5.176
Authors: Ary Gadelha; Vanessa Kiyomi Ota; Jose Paya Cano; Maria Isabel Melaragno; Marilia A C Smith; Jair de Jesus Mari; Rodrigo A Bressan; Sintia Iole Belangero; Gerome Breen Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240
Authors: Vanessa K Ota; Fernanda T Bellucco; Ary Gadelha; Marcos L Santoro; Cristiano Noto; Denise M Christofolini; Idaiane B Assunção; Karen M Yamada; Andrea K Ribeiro-dos-Santos; Sidney Santos; Jair J Mari; Marília A C Smith; Maria I Melaragno; Rodrigo A Bressan; João R Sato; Andrea P Jackowski; Sintia I Belangero Journal: PLoS One Date: 2014-02-03 Impact factor: 3.240
Authors: Irene M Lako; Johanna T W Wigman; Rianne M C Klaassen; Cees J Slooff; Katja Taxis; Agna A Bartels-Velthuis Journal: BMC Psychiatry Date: 2014-09-03 Impact factor: 3.630